Ann: Race Board and Management Team Changes, page-423

The question I asked myself was if anything has gone wrong that would inhibit or derail the train, and the answer was no. The main negative we point to is lost time & trust in the company. But if we still believe this is a buy, then it’s a buy. If they do correct course, 80c won’t be an option ever again.

Have we had uncertainty, yes
Have we lost time, yes
Opportunity cost, yes
Lost people, Yes.
Gained more, better? I’d argue Yes.
Any failures, clinically. No
Not pursuing Lung
Not pursuing Oral formula
Anything really been lost that we can’t repair, build on or get back?

Possibly our lead in the race but that’s not assured.

What we can add is:
Awareness on a global stage, BP etc Yes.
Awareness with KOLs, cardiologists & oncology experts.
Spoken with the FDA
Sheba 2 / Nagler incoming
RC220 incoming
DT believes he can do what’s needed with current funds which in my view means FTO & Cardio Validation before the $20m runs dry.

We can wait for the feel goods from management, dipping their own hands in, or any announcements to drop we all ready know are in the works, or we can invest against the grain and use this as an opportunity. I can’t personally see the point of hoping for 60,50,48c etc.